GENinCode (LON:GENI) Stock Price Up 9.4% – Should You Buy?

GENinCode Plc (LON:GENI) shot up 9.4% on Thursday . The company traded as high as GBX 0.90 and last traded at GBX 0.88. Approximately 7,631,066 shares were traded during mid-day trading, an increase of 31% from the average session volume of 5,831,207 shares. The stock had previously closed at GBX 0.80.

GENinCode Price Performance

The company has a debt-to-equity ratio of 117.74, a quick ratio of 15.88 and a current ratio of 0.93. The company has a 50-day simple moving average of GBX 0.96 and a two-hundred day simple moving average of GBX 1.17. The stock has a market cap of £6.59 million, a price-to-earnings ratio of -0.42 and a beta of 0.59.

GENinCode (LON:GENI) last issued its earnings results on Monday, June 8th. The company reported GBX (2.08) earnings per share for the quarter. GENinCode had a negative return on equity of 409.40% and a negative net margin of 185.47%.The firm had revenue of GBX 308 million for the quarter. As a group, equities research analysts forecast that GENinCode Plc will post -7.1299999 EPS for the current year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.